BRAF V600E inhibitors show improved outcomes in relapsed/refractory hairy cell leukemia.
Jessie Modlin, PharmD, BCOP
Advertisement
Articles by Jessie Modlin, PharmD, BCOP
Peer Reviewed
This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.
Peer Reviewed
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.
Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.
Systemic treatment options have historically been limited to traditional chemotherapy agents.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
2
Why Some Patients Do Not Respond to GLP-1 Therapies
3
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
4
GIRE Combination Shows PFS Benefit in First-Line Metastatic Breast Cancer Treatment, Earning FDA Priority Review
5